Is there a link between the prevalence of cardiovascular disease, diabetes, kidney disease, chronic obstructive pulmonary disease and malignancies and the severity of COVID-19 within the BAME population?

Aims: COVID-19 has been a big public health challenge around the world in the past several months. The aim of this study is to describe the epidemic and report of fatality of confirmed cases of COVID-19 in the Mexican state of Guanajuato, until October 2, 2020. Study Design: Cross-sectional, quantitative, analytical study. Place and Duration of Study: Registries of confirmed cases for COVID-19 in Mexican population from January until October 2, 2020, from National System of Epidemiological Surveillance/ General Direction of Epidemiology/ Secretary of Health, Mexico. Methodology: Based on the National Epidemiological Surveillance System Database from Mexico was used in this study. Data were collected on age, sex, comorbidities (i.e., diabetes, chronic obstructive pulmonary disease, asthma, hypertension, cardiovascular disease, immunosuppression, chronic kidney disease, obesity, and smoking), date of death, and real-time reverse transcription polymerase test results. Statistical analyses used were Case Fatality Ratio, Chi- squared test and P-value to show relationships among variables. Odds Ratio and confidence intervals at 95% were reported to show the effect of comorbidities on death due to COVID-19. Also, a Bayesian network model was fitted to assess the statistical dependence among risk factors, comorbidities, and death. Results: There were 100,109 suspected cases, of which 41.69% were positive for SARS-CoV-2. Being older than 60 and male had a higher effect on fatality by COVID-19. In Guanajuato state, 1,457 (48.68%) of deaths occurred in Mexican Institute of Social Security, with a case fatality ratio of 15.63%; meanwhile, in the Ministry of Health from Guanajuato State occurred 1,260 (42.10%) of the deaths with a case fatality ratio of 4.14%. Diabetes (OR 5.16, CI95% 4.77–5.59), chronic obstructive pulmonary disease (OR 6.34, CI95% 5.37–7.49), immunosuppression (OR 2.85, CI95% 2.17–3.76), cardiovascular disease (OR 4.20, CI95% 3.51–5.02), hypertension (OR 4.74, CI95% 4.39–5.11), chronic kidney disease (OR 6.27, CI95% 5.30–7.42), obesity (OR 1.87, CI95% 1.72–2.03), and smoking (OR 1.60, CI95% 1.41–1.81) had effect on death by COVID-19. Asthma had a preventive effect on death (OR=0.72, CI95% 0.54–0.97), but this effect is diluted after adjusting by sex and age. In all cases, age and sex, acted as confounder. Conclusion: Among the Guanajuato population with COVID-19, the main risk factor for dying were age and sex. However, diabetes, chronic obstructive pulmonary disease, immunosuppression, cardiovascular disease, chronic kidney disease, obesity, and smoking are risk factors for dying. Although, comorbidities and risk factors are highly correlated. HIV/AIDS has no effect on fatality from SARS-CoV-2 disease and whereas asthma shows to be a protective factor.

Download Full-text

Analysis of fatality of cases by the new coronavirus, in the Mexican state of Guanajuato: A cross-sectional study

10.21203/rs.3.rs-112119/v1 ◽

2020 ◽

Author(s):

Nicolas Padilla-Raygoza ◽

Gilberto Flores-Vargas ◽

Efrain Navarro-Olivos ◽

Elia Lara-Lona ◽

Maria de Gallardo-Luna ◽

...

Keyword(s):

Cardiovascular Disease ◽

Chronic Obstructive Pulmonary Disease ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Pulmonary Disease ◽

Case Fatality ◽

Chronic Obstructive ◽

Obstructive Pulmonary Disease ◽

Case Fatality Ratio ◽

Male Sex

Abstract Background. The spread of infection and disease of SARS-CoV-2 is in all the world affecting more than 200 countries. Mexico has high new cases of disease and death for COVID-19. Although Guanajuato state also has a high number of new cases, the fatality of cases is below the mean in Mexico.Methods. It was a cross-sectional design, using the database of National Epidemiological Surveillance System in Mexico. It was collected data about age, sex, comorbidities (diabetes, chronic obstructive pulmonary disease, asthma, hypertension, cardiovascular disease, immunosuppression, chronic kidney disease, obesity and smoking), date of death, and real-time reverse transcription polymerase test. The statistical analysis was using Case Fatality Ratio, Chi squared test and P-value to show relationship among variables and Odds Ratio and confidence intervals at 95% to show the effect of comorbidities on death due to COVID-19.Results. There were 100,109 suspected cases, 41.69% were positive for SARS-CoV-2. Age from 50 or higher and male sex had higher effect on fatality by COVID-19. In Guanajuato state, 48.68% of deaths occurred in Instituto Mexicano del Seguro Social, with a case fatality ratio 15.63% and in the Secretaría de Salud del estado de Guanajuato occurred 42.10% of the deaths with a case fatality ratio of 4.14%. Diabetes (OR 5.16, CI95% 4.77–5.59), chronic obstructive pulmonary disease (OR 6.34, CI95% 5.37–7.49), immunosuppression (OR 2.85, CI95% 2.17–3.76), cardiovascular disease (OR 4.20, CI95% 3.51–5.02), hypertension (OR 4.74, CI95% 4.39–5.11), chronic kidney disease (OR 6.27, CI95% 5.30–7.42), obesity (OR 1.87, CI95% 1.72–2.03), and smoking (OR 1.60, CI95% 1.41–1.81) had effect on death by COVID-19. In all cases age and male sex, acted as confounder. Asthma had a preventive effect on death by COVID-19 (OR=0.72, CI95% 0.54–0.97) Conclusion. Among the Guanajuato population with COVID-19, the main risk factor for dying were advanced age and male sex; diabetes, chronic obstructive pulmonary disease, immunosuppression, cardiovascular disease, chronic kidney disease, obesity, and smoking are risk factors for dying from COVID-19. HIV/AIDS has no effect on fatality from SARS-CoV-2 disease. Asthma is shown as a protective factor for dying from COVID-19.

Download Full-text

The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up

European Journal of Preventive Cardiology ◽

10.1177/2047487317751955 ◽

2018 ◽

Vol 25 (4) ◽

pp. 377-387 ◽

Cited By ~ 7

Author(s):

Michel Komajda ◽

Mathieu Kerneis ◽

Luigi Tavazzi ◽

Serban Balanescu ◽

Francesco Cosentino ◽

...

Keyword(s):

Cardiovascular Disease ◽

Chronic Obstructive Pulmonary Disease ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Pulmonary Disease ◽

Clinical Outcomes ◽

Chronic Obstructive ◽

Obstructive Pulmonary Disease ◽

History Of

Aim Chronic ischaemic cardiovascular disease (CICD) remains a leading cause of morbidity and mortality worldwide. The CICD Pilot Registry enrolled 2420 patients across 10 European Society of Cardiology countries prospectively to describe characteristics, management strategies and clinical outcomes in this setting. We report here the six-month outcomes. Methods and results From the overall population, 2203 patients were analysed at six months. Fifty-eight patients (2.6%) died after inclusion; 522 patients (23.7%) experienced all-cause hospitalisation or death. The rate of prescription of angiotensin-converting enzyme inhibitors, beta-blockers and aspirin was mildly decreased at six months (all P < 0.02). Patients who experienced all-cause hospitalisation or death were older, more often had a history of non-ST-segment elevation myocardial infarction, of chronic kidney disease, peripheral revascularisation and/or chronic obstructive pulmonary disease than those without events. Independent predictors of all-cause mortality/hospitalisation were age (hazard ratio (HR) 1.17, 95% confidence interval (CI) 1.07–1.27) per 10 years, and a history of previous peripheral revascularisation (HR 1.45, 95% CI 1.03–2.03), chronic kidney disease (HR 1.31, 95% CI 1.0–1.68) or chronic obstructive pulmonary disease (HR 1.42, 95% CI 1.06–1.91, all P < 0.05). We observed a higher rate of events in eastern, western and northern countries compared to southern countries and in cohort 1. Conclusion In this contemporary European registry of CICD patients, the rate of severe clinical outcomes at six months was high and was influenced by age, heart rate and comorbidities. The medical management of this condition remains suboptimal, emphasising the need for larger registries with long-term follow-up. Ad-hoc programmes aimed at implementing guidelines adherence and follow-up procedures are necessary, in order to improve quality of care and patient outcomes.

Download Full-text